WO2011103128A1 - Traitement du syndrome métabolique avec de nouvelles amines - Google Patents

Traitement du syndrome métabolique avec de nouvelles amines Download PDF

Info

Publication number
WO2011103128A1
WO2011103128A1 PCT/US2011/024996 US2011024996W WO2011103128A1 WO 2011103128 A1 WO2011103128 A1 WO 2011103128A1 US 2011024996 W US2011024996 W US 2011024996W WO 2011103128 A1 WO2011103128 A1 WO 2011103128A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
compound
lower alkyl
hydrogen
substituted lower
Prior art date
Application number
PCT/US2011/024996
Other languages
English (en)
Inventor
James R. Hauske
Original Assignee
Ampla Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ampla Pharmaceuticals Inc. filed Critical Ampla Pharmaceuticals Inc.
Publication of WO2011103128A1 publication Critical patent/WO2011103128A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Definitions

  • Obesity is a condition of complex origin. Increasing evidence suggests that obesity is not a simple problem of self-control but is a complex disorder involving appetite regulation and energy metabolism. In addition, obesity is associated with a variety of conditions associated with increased morbidity and mortality in a population. Although the etiology of obesity is not definitively established, genetic, metabolic, biochemical, cultural and psychosocial factors are believed to contribute. In general, obesity has been described as a condition in which excess body fat puts an individual at a health risk.
  • Metabolic syndrome also known as “syndrome X,” “dysmetabolic syndrome,”
  • metabolic syndrome has become increasingly common in the United States. It is estimated that about 47 million adults in the United States have the syndrome.
  • Metabolic syndrome is generally a constellation of metabolic disorders that all result from, or are associated with, a primary disorder of insulin resistance.
  • Insulin resistance syndrome is characterized by disorders in which the body cannot use insulin efficiently and the body's tissues do not respond normally to insulin. As a result, insulin levels become elevated in the body's attempt to overcome the resistance to insulin. The elevated insulin levels lead, directly or indirectly, to the other metabolic abnormalities.
  • Metabolic syndrome is typically characterized by a group of metabolic risk factors that include 1) central obesity; 2) atherogenic dyslipidemia (blood fat disorders comprising mainly high triglycerides (“TG”) and low HDL-cholesterol (interchangeably referred to herein as "HDL”) that foster plaque buildups in artery walls); 3) raised blood pressure; 4) insulin resistance or glucose intolerance (the body can't properly use insulin or blood sugar); 5) prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor in the blood); and 6) a proinflammatory state (e.g., elevated high-sensitivity C-reactive protein in the blood).
  • NEP National Cholesterol Education Program
  • ATP Adult Treatment Panel
  • a circumference greater than 102 cm for men, and greater than 88 cm for women b) a triglyceride level greater than 150 mg/dl; c) an HDL-cholesterol less than 40 mg/dl for men, and less than 50 mg/dl for women; d) a blood pressure greater than or equal to 130/85 mmHg; and e) a fasting glucose greater than 110 mg/dl.
  • metabolic syndrome involves four general factors: obesity; diabetes; hypertension; and high lipids. According to the NCEP ATP III guidelines above, the presence of at least three of these factors meets the medical diagnosis of metabolic syndrome.
  • a person with the metabolic syndrome is at an increased risk of coronary heart disease, other diseases related to plaque buildups in artery walls (e.g., stroke and peripheral vascular disease), prostate cancer, and type 2 diabetes. It is also known that when diabetes occurs, the high risk of cardiovascular complications increases.
  • patients suffering from the syndrome are prescribed a change in lifestyle, e.g., an increase in exercise and a change to a healthy diet.
  • the goal of exercise and diet programs is to reduce body weight to within 20% of the "ideal" body weight calculated for age and height.
  • diet and exercise regimens are supplemented with treatments for lipid abnormalities, clotting disorders, and hypertension.
  • patients with the syndrome typically have several disorders of coagulation that make it easier to form blood clots within blood vessels. These blood clots are often a precipitating factor in developing heart attacks. Patients with the syndrome are often placed on daily aspirin therapy to specifically help prevent such clotting events.
  • high blood pressure is present in more than half the people with the syndrome, and in the setting of insulin resistance, high blood pressure is especially important as a risk factor.
  • LDL LDL- cholesterol
  • the present invention provides novel compounds, including purified preparations of those compounds.
  • the invention provides compounds of formula I or a pharmaceuticall acceptable salt thereof:
  • X represents H or an optionally substituted aryl or heteroaryl ring system
  • Y represents an optionally substituted aryl or heteroaryl ring system
  • Z represents O or H 2 ;
  • z represents an integer from 0 to 4.
  • R 1 represents hydrogen or optionally substituted lower alkyl
  • R 2 and R 2 each independently represent hydrogen or optionally substituted lower alkyl, or R 2 and R 2 taken together with the carbon to which they are attached form an optionally substituted four- to six-membered cyclic ring system; and R 20 and R 21 each independently for each occurrence represent a substituent.
  • the compound of formula I is represented by formula la or a pharmaceutically acceptable salt thereof:
  • Z represents O or H 2 ;
  • n an integer from 0 to 5;
  • o represents an integer from 0 to 5;
  • p represents an integer from 0 to 2;
  • R 1 represents hydrogen or optionally substituted lower alkyl
  • R 2 and R 2 each independently represent hydrogen or optionally substituted lower alkyl, or R 2 and R 2 taken together with the carbon to which they are attached form an optionally substituted four- to six-membered cyclic ring system;
  • R 4 , R 20 , and R 21 each independently for each occurrence, represents a substituent
  • R 10 , R 11 , R 12 , R 13 , and R 14 each independently represent hydrogen or a substituent.
  • the invention provides compounds of formula II or a pharmaceutically acceptable salt thereof:
  • X represents H or an optionally substituted aryl or heteroaryl ring system
  • Y represents an optionally substituted aryl or heteroaryl ring system
  • z represents an integer from 0 to 4.
  • R 1 represents hydrogen or optionally substituted lower alkyl
  • R 2 and R 2 each independently represent hydrogen or optionally substituted lower alkyl, or R 2 and R 2 taken together with the carbon to which they are attached form an optionally substituted four- to six-membered cyclic ring system;
  • R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , and R 32 each independently represent hydrogen or a substituent
  • R 49 and R 50 each independently represent hydrogen or an optionally substituted lower alkyl, or R 49 and R 50 taken together with the carbon to which they are attached form an optionally substituted three- to six-membered cyclic ring system.
  • the compound of formula II is represented by formula
  • n an integer from 0 to 5;
  • R 1 represents hydrogen or optionally substituted lower alkyl
  • R 2 and R 2 each independently represent hydrogen or optionally substituted lower alkyl, or R 2 and R 2 taken together with the carbon to which they are attached form an optionally substituted four- to six-membered cyclic ring system
  • R 4 independently for each occurrence, represents a substituent
  • R 10 , R 11 , R 12 , R 13 , R 14 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , and R 32 each
  • R 49 and R 50 each independently represent hydrogen or an optionally substituted lower alkyl, or R 49 and R 50 taken together with the carbon to which they are attached form an optionally substituted three- to six-membered cyclic ring system.
  • the present invention provides a method of treating obesity, metabolic syndrome or a disorder associated with metabolic syndrome (e.g. , obesity, diabetes, hypertension, and hyperlipidemia) in a mammal comprising administering to a mammal suffering from obesity, metabolic syndrome or a disorder associated with metabolic syndrome (e.g. , obesity, diabetes, hypertension, and hyperlipidemia) a compound of the invention (e.g., a compound of formula I or II).
  • the disorder associated with metabolic syndrome is diabetes.
  • the mammal is a human.
  • the present invention provides certain novel compounds, including purified preparations of those compounds.
  • the invention provides compounds of formula I or a pharmaceuticall acceptable salt thereof:
  • X represents H or an optionally substituted aryl or heteroaryl ring system
  • Y represents an optionally substituted aryl or heteroaryl ring system
  • p represents an integer from 0 to 2;
  • z represents an integer from 0 to 4.
  • R 1 represents hydrogen or optionally substituted lower alkyl
  • R 2 and R 2 each independently represent hydrogen or optionally substituted lower alkyl, or R 2 and R 2 taken together with the carbon to which they are attached form an optionally substituted four- to six-membered cyclic ring system; and R 20 and R 21 each independently for each occurrence represent a substituent.
  • X represents an optionally substituted phenyl or thiophene.
  • X is optionally substituted with optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or nitro.
  • Y represents an optionally substituted phenyl or naphthyl ring system.
  • Y is optionally substituted with optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or nitro.
  • R 20 and R 21 each independently represent optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or nitro.
  • o 0.
  • p is 0.
  • R 1 represents hydrogen
  • R 2 and R 2 are each hydrogen.
  • R 2 is hydrogen and R 2 is optionally substituted lower alkyl, such as methyl or -CH 2 OCH 3 .
  • the compound of formula I is represented by formula la or a pharmaceutically acceptable salt thereof:
  • Z represents O or H 2 ;
  • n an integer from 0 to 5;
  • o represents an integer from 0 to 5;
  • p represents an integer from 0 to 2;
  • R 1 represents hydrogen or optionally substituted lower alkyl
  • R 2 and R 2 each independently represent hydrogen or optionally substituted lower alkyl, or R 2 and R 2 taken together with the carbon to which they are attached form an optionally substituted four- to six-membered cyclic ring system;
  • R 4 , R 20 , and R 21 each independently for each occurrence, represents a substituent;
  • R 10 , R 11 , R 12 , R 13 , and R 14 each independently represent hydrogen or a substituent.
  • R 10 , R 11 , R 12 , R 13 , and R 14 each independently represent hydrogen, optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or nitro.
  • R 10 , R 11 , R 13 , and R 14 are hydrogen, and R 12 is optionally substituted lower alkyl. In certain such embodiments, R 12 is trifluoromethyl.
  • R 4 , R 20 , and R 21 each independently for each occurrence represents optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or nitro.
  • R 1 represents hydrogen
  • R 2 and R 2 are each hydrogen.
  • R 2 is hydrogen and R 2 is optionally substituted lower alkyl, such as methyl or -CH 2 OCH 3 .
  • m is 0.
  • o is 0. In certain embodiments, p is 0.
  • a compound of formula la has the structure 1,
  • the invention further provides compounds of formula II or a pharmaceutically acceptable salt thereof:
  • X represents H or an optionally substituted aryl or heteroaryl ring system
  • Y represents an optionally substituted aryl or heteroaryl ring system
  • z represents an integer from 0 to 4.
  • R 1 represents hydrogen or optionally substituted lower alkyl
  • R 2 and R 2 each independently represent hydrogen or optionally substituted lower alkyl, or R 2 and R 2 taken together with the carbon to which they are attached form an optionally substituted four- to six-membered cyclic ring system;
  • R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , and R 32 each independently represent hydrogen or a substituent;
  • R 49 and R 50 each independently represent hydrogen or an optionally substituted lower alkyl, or R 49 and R 50 taken together with the carbon to which they are attached form a three- to six-membered cyclic ring system.
  • X represents an optionally substituted phenyl or thiophene.
  • X is optionally substituted with optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or nitro.
  • Y represents an optionally substituted phenyl or naphthyl ring system.
  • Y is optionally substituted with optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or nitro.
  • R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , and R 32 each independently represent hydrogen, optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or
  • R , R , R , R , R , and R each independently represent hydrogen, R 25 represents optionally substituted alkoxyl, and R 30 represents halogen. In certain such embodiments, R 25 represents methoxy, and R 30 represents chloro.
  • R 1 represents hydrogen
  • R 2 and R 2 are each hydrogen.
  • R 2 is hydrogen and R 2 is optionally substituted lower alkyl, such as methyl or -CH2OCH3.
  • X represents an optionally substituted aryl or heteroaryl ring system. In certain embodiments, X represents an optionally substituted aryl or heteroaryl ring system.
  • R 49 and R 50 are each hydrogen.
  • R 49 and R 50 taken together with the carbon to which they are attached form an optionally substituted cyclopropane or cyclobutane ring.
  • the compound of formula II is represented by formula Ila or a pharmaceuticall acceptable salt thereof:
  • n an integer from 0 to 5;
  • R 1 represents hydrogen or optionally substituted lower alkyl
  • R 2 and R 2 each independently represent hydrogen or optionally substituted lower alkyl, or R 2 and R 2 taken together with the carbon to which they are attached form an optionally substituted four- to six-membered cyclic ring system;
  • R 4 independently for each occurrence, represents a substituent;
  • R 10 , R 11 , R 12 , R 13 , R 14 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , and R 32 each
  • R 49 and R 50 each independently represent hydrogen or an optionally substituted lower alkyl, or R 49 and R 50 taken together with the carbon to which they are attached form an optionally substituted three- to six-membered cyclic ring system.
  • R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , and R 32 each independently represent hydrogen, optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or nitro.
  • R 24 , R 26 , R 27 , R 28 , R 29 , R 31 , and R 32 each independently represent hydrogen, R 25 represents optionally substituted alkoxyl, and R 30 represents halogen. In certain such embodiments, R 25 represents methoxy, and R 30 represents chloro.
  • R 10 , R 11 , R 12 , R 13 , and R 14 each independently represent hydrogen, optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or nitro.
  • R 10 , R 11 , R 13 , and R 14 are hydrogen, and R 12 is optionally substituted lower alkyl. In certain such embodiments, R 12 is trifluoromethyl.
  • R 4 independently for each occurrence, represents optionally substituted lower alkyl, halogen, hydroxyl, carboxyl, ester, optionally substituted alkoxycarbonyl, acyl, thioester, thioacyl, thioether, optionally substituted alkoxyl, amino, amido, acylamino, cyano, or nitro.
  • R 1 represents hydrogen
  • R 2 and R 2 are each hydrogen.
  • R 2 is hydrogen and R 2 is optionally substituted lower alkyl, such as methyl or -CH 2 OCH 3 .
  • m is 0.
  • R 49 and R 50 are each hydrogen.
  • R 49 and R 50 taken together with the carbon to which they are attached form an optionally substituted cyclopropane or cyclobutane ring.
  • a compound of formula Ila has the structure 3,
  • compounds of the invention may be racemic. In other embodiments, compounds of the invention may be enriched in one enantiomer. For example, a compound of the invention may have greater than 30% ee, 40% ee, 50% ee, 60%) ee, 70%> ee, 80%> ee, 90%> ee, or even 95% or greater ee. In certain embodiments, compounds of the invention may be enriched in one or more diastereomer. For example, a compound of the invention may have greater than 30% de, 40% de, 50% de, 60% de, 70% de, 80% de, 90% de, or even 95% or greater de.
  • the present invention also relates to a method of treating obesity in a mammal.
  • the invention further relates to a method of minimizing metabolic risk factors associated with obesity, such as hypertension, diabetes and dyslipidemia.
  • the methods comprise administering to a mammal in need of such treatment an effective anti-obesity dose of a compound of the invention (e.g. , a compound of formula I or II, or a pharmaceutically acceptable salt thereof).
  • the mammal is a human.
  • the present invention provides a method of treating or preventing metabolic syndrome or a disorder associated with metabolic syndrome (e.g. , obesity, diabetes, hypertension, and hyperlipidemia) in a mammal comprising administering to a mammal suffering from metabolic syndrome or a disorder associated with metabolic syndrome (e.g., obesity, diabetes, hypertension, and hyperlipidemia) an effective dose of a compound of the invention (e.g., a compound of formula I or II, or a pharmaceutically acceptable salt thereof).
  • a compound of the invention e.g., a compound of formula I or II, or a pharmaceutically acceptable salt thereof.
  • the disorder associated with metabolic syndrome is diabetes.
  • the mammal is a human.
  • the present invention relates to methods of treatment with a compound of formula I or II, or a pharmaceutically acceptable salt thereof.
  • the therapeutic preparation may be enriched to provide predominantly one enantiomer of a compound (e.g., of formula I or II).
  • An enantiomerically enriched mixture may comprise, for example, at least 60 mol percent of one enantiomer, or more preferably at least 75, 90, 95, or even 99 mol percent.
  • the compound enriched in one enantiomer is substantially free of the other enantiomer, wherein substantially free means that the substance in question makes up less than 10%, or less than 5%>, or less than 4%>, or less than 3%>, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g., in the composition or compound mixture.
  • substantially free means that the substance in question makes up less than 10%, or less than 5%>, or less than 4%>, or less than 3%>, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g., in the composition or compound mixture.
  • a composition or compound mixture contains 98 grams of a first enantiomer and 2 grams of a second enantiomer, it would be said to contain 98 mol percent of the first enantiomer and only 2% of the second enantiomer.
  • the therapeutic preparation may be enriched to provide predominantly one diasteriomer of a compound (e.g., of formula I or II).
  • a diasteriomerically enriched mixture may comprise, for example, at least 60 mol percent of one diasteriomer, or more preferably at least 75, 90, 95, or even 99 mol percent.
  • Compounds suitable for use in methods of the invention include any compound of the invention as set forth above (e.g., a compound represented by formula I or II, or a pharmaceutically acceptable salt thereof).
  • One aspect of the present invention provides a pharmaceutical composition suitable for use in a human patient, or for veterinary use, comprising an effective amount of a compound of the invention (e.g., a compound of formula I or II, or a pharmaceutically acceptable salt thereof), and one or more pharmaceutically acceptable carriers.
  • the pharmaceutical compositions may be for use in treating or preventing obesity, metabolic syndrome, or a disorder associated with metabolic syndrome (e.g., obesity, diabetes, hypertension, and hyperlipidemia).
  • the pharmaceutical preparations have a low enough pyrogen activity to be suitable for use in a human patient, or for veterinary use.
  • the pharmaceutical preparation comprises an effective amount of a compound of the invention (e.g., a compound of formula I or II, or a pharmaceutically acceptable salt thereof).
  • Compounds of the invention may be used in the manufacture of medicaments for the treatment of any diseases disclosed herein.
  • the term "obesity" includes both excess body weight and excess adipose tissue mass in an animal.
  • An obese individual is one having a body mass index of > 30 kg/m 2 . While the animal is typically a human, the invention also encompasses the treatment of non-human mammals.
  • the treatment of obesity contemplates not only the treatment of individuals who are defined as “obese”, but also the treatment of individuals with weight gain that if left untreated may lead to the development of obesity.
  • Healthcare providers refers to individuals or organizations that provide healthcare services to a person, community, etc.
  • Examples of “healthcare providers” include doctors, hospitals, continuing care retirement communities, skilled nursing facilities, subacute care facilities, clinics, multispecialty clinics, freestanding ambulatory centers, home health agencies, and HMO's.
  • hydrate refers to a composition formed by the association of water with a compound.
  • metabolite is intended to encompass compounds that are produced by metabolism of the parent compound under normal physiological conditions. For example, an N-methyl group may be cleaved to produce the corresponding N- desmethyl metabolite, or an amide may be cleaved to the corresponding carboxylic acid and amine.
  • Preferred metabolites of the present invention include those that exhibit activity suitable for the treatment of obesity, metabolic syndrome, or a disorder associated with metabolic syndrome.
  • a therapeutic that "prevents" a disorder or condition refers to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.
  • solvate refers to a composition formed by solvation (e.g., a composition formed by the combination of solvent molecules with molecules or ions of the solute, such as with molecules or ions of a compound of the invention).
  • treating includes prophylactic and/or therapeutic treatments.
  • prophylactic or therapeutic treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic (i.e., it protects the host against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
  • acyl is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.
  • acylamino is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(0)NH-.
  • acyloxy is art-recognized and refers to a group represented by the general formula hydrocarbylC(0)0-, preferably alkylC(0)0-.
  • alkoxy refers to an alkyl group, preferably a lower alkyl group, having an oxygen attached thereto.
  • Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.
  • alkoxyalkyl refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O-alkyl.
  • alkenyl refers to an aliphatic group containing at least one double bond and is intended to include both "unsubstituted alkenyls" and “substituted alkenyls", the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the alkenyl group. Such substituents may occur on one or more carbons that are included or not included in one or more double bonds. Moreover, such substituents include all those
  • alkyl groups as discussed below, except where stability is prohibitive.
  • substitution of alkenyl groups by one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated.
  • alkyl refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups.
  • a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., Ci-C 30 for straight chains, C 3 -C 30 for branched chains), and more preferably 20 or fewer.
  • preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
  • alkyl (or “lower alkyl) as used throughout the specification, examples, and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having
  • substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone can include, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl
  • the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
  • the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), -CF 3 , -CN and the like.
  • Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, -CF 3 , -CN, and the like.
  • C x _ y when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain.
  • C x _ y alkyl refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc.
  • Co alkyl indicates a hydrogen where the group is in a terminal position, a bond if internal.
  • C 2 - y alkenyl and “C 2 _ y alkynyl” refer to substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
  • alkylamino refers to an amino group substituted with at least one alkyl group.
  • alkylthio refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-.
  • alkynyl refers to an aliphatic group containing at least one triple bond and is intended to include both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having
  • substituents replacing a hydrogen on one or more carbons of the alkynyl group may occur on one or more carbons that are included or not included in one or more triple bonds.
  • substituents include all those contemplated for alkyl groups, as discussed above, except where stability is prohibitive. For example, substitution of alkynyl groups by one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated.
  • amide refers to a group
  • R 9 and R 10 each independently represent a hydrogen or hydrocarbyl group, R 9 and R 10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
  • amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by
  • R 9 , R 10 , and R 10 each independently represent a hydrogen or a hydrocarbyl group, or R 9 and R 10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
  • aminoalkyl refers to an alkyl group substituted with an amino group.
  • aralkyl refers to an alkyl group substituted with an aryl group.
  • aryl as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon.
  • the ring is a 5- to 7-membered ring, more preferably a 6-membered ring.
  • aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
  • Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
  • R 9 and R 10 independently represent hydrogen or a hydrocarbyl group, such as an alkyl group, or R 9 and R 10 taken together with the intervening atom(s) complete a heterocycle having from 4 to 8 atoms in the ring structure.
  • carbocycle refers to a non-aromatic saturated or unsaturated ring in which each atom of the ring is carbon.
  • a carbocycle ring contains from 3 to 10 atoms, more preferably from 5 to 7 atoms.
  • Carbocyclylalkyl refers to an alkyl group substituted with a carbocycle group.
  • carbonate is art-recognized and refers to a group -OCO 2 -R 9 , wherein R 9 represents a hydrocarbyl group.
  • esters refers to a group -C(0)OR 9 wherein R 9 represents a hydrocarbyl group.
  • ether refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O- heterocycle and aryl-O-heterocycle. Ethers include "alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.
  • heteroalkyl and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.
  • heteroaryl and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
  • heteroaryl and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
  • Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
  • heteroatom as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.
  • heterocyclyl refers to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10- membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
  • heterocyclyl and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
  • Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
  • heterocyclylalkyl refers to an alkyl group substituted with a heterocycle group.
  • Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.
  • hydroxyalkyl refers to an alkyl group substituted with a hydroxy group.
  • lower when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer non-hydrogen atoms in the substituent, preferably six or fewer.
  • acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within the aryl group are not counted when counting the carbon atoms in the alkyl substituent).
  • polycyclyl refers to two or more rings ⁇ e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are "fused rings".
  • Each of the rings of the polycycle can be substituted or unsubstituted.
  • each ring of the polycycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.
  • substituted refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that
  • substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g. , which does not
  • the term "substituted" is contemplated to include all permissible substituents of organic compounds.
  • the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
  • the permissible substituents can be one or more and the same or different for appropriate organic compounds.
  • the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
  • Substituents can include any substituents described herein, for example, halogen, hydroxyl, alkyl, haloalkyl, alkenyl, alkynyl, carbonyl (such as carboxyl,
  • alkoxycarbonyl formyl, ketone, or acyl
  • thiocarbonyl such as thioester, thioacetate, or thioformate
  • alkoxyl phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, silyl, ether, cycloalkyl, heterocyclyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaralkyl, aralkyl, or aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
  • references to chemical moieties herein are understood to include substituted variants.
  • aryl group or moiety implicitly includes both substituted and unsubstituted variants.
  • sulfate is art-recognized and refers to the group -OSO3H, or a pharmaceutically acceptable salt thereof.
  • sulfonamide is art-recognized and refers to the group represented by the general formulae wherein R 9 and R 10 independently represents hydrogen or hydrocarbyl, such as alkyl, or R 9 and R 10 taken together with the intervening atom(s) complete a heterocycle having from 4 to 8 atoms in the ring structure.
  • sulfoxide is art-recognized and refers to the group -S(0)-R 9 , wherein R 9 represents a hydrocarbyl.
  • sulfonate is art-recognized and refers to the group SO 3 H, or a pharmaceutically acceptable salt thereof.
  • sulfone is art-recognized and refers to the group -S(0) 2 -R 9 , wherein R 9 represents a hydrocarbyl.
  • thioalkyl refers to an alkyl group substituted with a thiol group.
  • thioester refers to a group -C(0)SR 9 or -SC(0)R 9 wherein R 9 represents a hydrocarbyl.
  • thioether is equivalent to an ether, wherein the oxygen is replaced with a sulfur.
  • urea is art-recognized and may be represented by the general formula
  • R 9 and R 10 independently represent hydrogen or a hydrocarbyl, such as alkyl, or either occurrence of R 9 taken together with R 10 and the intervening atom(s) complete a heterocycle having from 4 to 8 atoms in the ring structure.
  • Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms.
  • the present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
  • Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
  • a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
  • diastereomeric salts may be formed with an appropriate optically active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
  • enantiomerically enriched mixtures and pure enantiomeric compounds can be prepared by using synthetic intermediates that are enantiomerically pure in combination with reactions that either leave the stereochemistry at a chiral center unchanged or result in its complete inversion.
  • Techniques for inverting or leaving unchanged a particular stereocenter, and those for resolving mixtures of stereoisomers are well known in the art, and it is well within the ability of one of skill in the art to choose an appropriate method for a particular situation. See, generally, Furniss et al. (eds.), Vogel's Encyclopedia of Practical Organic Chemistry 5 th Ed., Longman Scientific and Technical Ltd., Essex, 1991, pp. 809-816; and Heller, Acc. Chem. Res. 23: 128 (1990).
  • the amount of active agent(s) ⁇ e.g., a compound of the invention, such as a compound of formula I or II) administered can vary with the patient, the route of administration and the result sought. Optimum dosing regimens for particular patients can be readily determined by one skilled in the art.
  • Compounds of the invention may be administered to an individual in need thereof.
  • the individual is a mammal such as a human, or a non-human mammal.
  • the compound of the invention can be administered as a pharmaceutical composition containing, for example, the compound of the invention and a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil or injectable organic esters.
  • the aqueous solution is pyrogen free, or substantially pyrogen free, or has low enough pyrogen activity.
  • the excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs.
  • the pharmaceutical composition can be in dosage unit form such as tablet, capsule, sprinkle capsule, granule, powder, syrup, suppository, injection or the like.
  • the composition can also be present in a transdermal delivery system, e.g. , a skin patch.
  • low enough pyrogen activity refers to a preparation that does not contain a pyrogen in an amount that would lead to an adverse effect (e.g., irritation, fever, inflammation, diarrhea, respiratory distress, endotoxic shock, etc.) in a subject to which the preparation has been administered.
  • an adverse effect e.g., irritation, fever, inflammation, diarrhea, respiratory distress, endotoxic shock, etc.
  • the term is meant to encompass preparations that are free of, or substantially free of, an endotoxin such as, for example, a
  • LPS lipopolysaccharide
  • a pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize or to increase the absorption of a compound of the invention.
  • physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients.
  • the choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent depends, for example, on the route of administration of the composition.
  • the pharmaceutical composition (preparation) also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a compound of the invention. Liposomes, for example, which consist of phospholipids or other lipids, are nontoxic, physiologically acceptable and
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable carrier means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
  • a pharmaceutical composition (preparation) containing a compound of the invention can be administered to a subject by any of a number of routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, boluses, powders, granules, pastes for application to the tongue); sublingually; anally, rectally or vaginally (for example, as a pessary, cream or foam); parenterally (including intramusclularly, intravenously, subcutaneously or intrathecally as, for example, a sterile solution or suspension); nasally; intraperitoneally; subcutaneously; transdermally (for example as a patch applied to the skin); and topically (for example, as a cream, ointment or spray applied to the skin).
  • routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, boluses, powders
  • the compound may also be formulated for inhalation.
  • a compound of the invention may be simply dissolved or suspended in sterile water. Details of appropriate routes of administration and compositions suitable for same can be found in, for example, U.S. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, as well as in patents cited therein. The most preferred route of administration is the oral route.
  • the formulations of the present invention may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
  • the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.
  • compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in- water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
  • a compound of the present invention may also be administered as a bolus, electuary or paste.
  • the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cety
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
  • compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • embedding compositions that can be used include polymeric substances and waxes.
  • the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
  • Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents, e
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar- agar and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar- agar and tragacanth, and mixtures thereof.
  • Formulations of the pharmaceutical compositions of the invention for rectal, vaginal, or urethral administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • compositions can be formulated for delivery via a catheter, stent, wire, or other intraluminal device. Delivery via such devices may be especially useful for delivery to the bladder, urethra, ureter, rectum, or intestine.
  • Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
  • Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
  • Ophthalmic formulations are also contemplated as being within the scope of this invention.
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical
  • administration usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
  • compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
  • the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form.
  • delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
  • Injectable depot forms are made by forming microencapsuled matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide.
  • the rate of drug release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
  • composition containing, for example, 0.1 to 99.5% (more preferably,
  • the addition of the active compound of the invention to animal feed is preferably accomplished by preparing an appropriate feed premix containing the active compound in an effective amount and incorporating the premix into the complete ration.
  • an intermediate concentrate or feed supplement containing the active ingredient can be blended into the feed.
  • feed premixes and complete rations can be prepared and administered are described in reference books (such as "Applied Animal Nutrition", W.H. Freedman and CO., San Francisco, U.S.A., 1969 or “Livestock Feeds and Feeding” O and B books, Corvallis, Ore., U.S.A., 1977).
  • Methods of introduction may also be provided by rechargeable or
  • biodegradable devices Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinaceous biopharmaceuticals.
  • a variety of biocompatible polymers including hydrogels, including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a compound at a particular target site.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a compound of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
  • the effective daily dose of the active compound may be any suitable daily dose of the active compound. If desired, the effective daily dose of the active compound may be any suitable daily dose of the active compound.
  • the active compound may be administered two or three times daily. In preferred embodiments, the active compound will be administered once daily.
  • the patient receiving this treatment is any animal in need, including primates, in particular humans, and other mammals such as equines, cattle, swine and sheep; and poultry and pets in general.
  • a compound of the present invention may be used alone or conjointly administered with another type of therapeutic agent.
  • the phrase "conjoint administration” refers to any form of administration of two or more different therapeutic compounds such that the second compound is administered while the previously administered therapeutic compound is still effective in the body (e.g., the two compounds are simultaneously effective in the patient, which may include synergistic effects of the two compounds).
  • the different therapeutic compounds can be administered either in the same formulation or in a separate formulation, either concomitantly or sequentially.
  • an individual who receives such treatment can benefit from a combined effect of different therapeutic compounds.
  • a compound of the present invention may be administered conjointly with another treatment for diabetes including, but not limited to, sulfonyl ureas (e.g., chlorpropamide, tolbutamide, glyburide, glipizide, or glimepiride), medications that decrease the amount of glucose produced by the liver (e.g., metformin), meglitinides (e.g., repaglinide or nateglinide), medications that decrease the absorption of carbohydrates from the intestine (e.g., alpha glucosidase inhibitors such as acarbose), medications that effect glycemic control (e.g., pramlintide or exenatide), DPP-IV inhibitors (e.g., sitagliptin), insulin treatment, or combinations of the above.
  • sulfonyl ureas e.g., chlorpropamide, tolbutamide, glyburide, glipizide, or glimepiride
  • a compound of the present invention may be administered conjointly with another treatment for obesity including, but not limited to, orlistat, sibutramine, phendimetrazine, phentermine, diethylpropion,
  • benzphetamine mazindol, dextroamphetamine, rimonabant, cetilistat, GT 389-255, APD356, pramlintide/AC137, PYY3-36, AC 162352/PYY3-36, oxyntomodulin, TM 30338, AOD 9604, oleoyl-estrone, bromocriptine, ephedrine, leptin, pseudoephedrine, or pharmaceutically acceptable salts thereof.
  • a compound of the present invention will be administered to a subject (e.g., a mammal, preferably a human) in a therapeutically effective amount (dose).
  • a subject e.g., a mammal, preferably a human
  • dose a therapeutically effective amount
  • therapeutically effective amount is meant the concentration of a compound that is sufficient to elicit the desired therapeutic effect (e.g. , treatment of obesity, metabolic syndrome, or a disorder associated with metabolic syndrome, such as obesity, diabetes, hypertension, and hyperlipidemia). It is generally understood that the effective amount of the compound will vary according to the weight, sex, age, and medical history of the subject.
  • the effective amount may include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the compound, and, if desired, another type of therapeutic agent being administered with the compound of the invention.
  • a larger total dose can be delivered by multiple administrations of the agent. Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison's Principles of Internal Medicine 13 ed., 1814- 1882, herein incorporated by reference).
  • compounds of the invention include the pharmaceutically acceptable salts of compounds of the invention.
  • the compounds of the invention, including their pharmaceutically acceptable salts can also exist as various solvates, such as with water (e.g., a hydrate, such as a hemihydrate, monohydrate, dihydrate, trihydrate, or tetrahydrate), methanol, ethanol, dimethylformamide, and the like. Mixtures of such solvates can also be prepared.
  • the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention.
  • the source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent. Suitable solvents and procedures for the preparation of solvates and hydrates can generally be selected by a skilled artisan. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
  • salts includes salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic,
  • salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19).
  • Certain specific compounds of the present invention may contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs form the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
  • diastereomeric salts may be formed with an appropriate optically active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
  • enantiomerically enriched mixtures and pure enantiomeric compounds can be prepared by using synthetic intermediates that are enantiomerically pure in combination with reactions that either leave the stereochemistry at a chiral center unchanged or result in its complete inversion.
  • Techniques for inverting or leaving unchanged a particular stereocenter, and those for resolving mixtures of stereoisomers are well known in the art, and it is well within the ability of one of skill in the art to choose an appropriate method for a particular situation. See, generally, Furniss et al. (eds.), Vogel's Encyclopedia of Practical Organic Chemistry 5 th Ed., Longman Scientific and Technical Ltd., Essex, 1991, pp. 809-816; and Heller, Acc. Chem. Res. 23: 128 (1990).
  • wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene
  • BHT lecithin
  • propyl gallate alpha-tocopherol
  • metal chelating agents such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • the present invention provides a kit comprising:
  • the invention relates to a method for conducting a pharmaceutical business, by manufacturing a formulation or kit as described herein, and marketing to healthcare providers the benefits of using the formulation or kit in the treatment of obesity, metabolic syndrome, or a disorder associated with metabolic syndrome ⁇ e.g., obesity, diabetes, hypertension, and hyperlipidemia).
  • a pharmaceutical business by manufacturing a formulation or kit as described herein, and marketing to healthcare providers the benefits of using the formulation or kit in the treatment of obesity, metabolic syndrome, or a disorder associated with metabolic syndrome ⁇ e.g., obesity, diabetes, hypertension, and hyperlipidemia).
  • the invention provides a method for conducting a pharmaceutical business, by providing a distribution network for selling a formulation or kit as described herein, and providing instruction material to patients or physicians for using the formulation to treat obesity, metabolic syndrome, or a disorder associated with metabolic syndrome (e.g., obesity, diabetes, hypertension, and hyperlipidemia).
  • a disorder associated with metabolic syndrome e.g., obesity, diabetes, hypertension, and hyperlipidemia.
  • the present invention relates to a method for conducting a pharmaceutical business, by providing a distribution network for selling a formulation or kit as described herein, and providing instruction material to patients or physicians for using the formulation to treat obesity, metabolic syndrome, or a disorder associated with metabolic syndrome (e.g. , obesity, diabetes, hypertension, and hyperlipidemia).
  • a disorder associated with metabolic syndrome e.g. , obesity, diabetes, hypertension, and hyperlipidemia
  • the invention comprises a method for conducting a pharmaceutical business, by determining an appropriate formulation and dosage of a compound of the invention (e.g., a compound of formula I or II, or a pharmaceutically acceptable salt thereof) to be administered in the treatment of obesity, metabolic syndrome, or a disorder associated with metabolic syndrome (e.g., obesity, diabetes, hypertension, and hyperlipidemia), conducting therapeutic profiling of identified formulations for efficacy and toxicity in animals, and providing a distribution network for selling an identified preparation as having an acceptable therapeutic profile.
  • the method further includes providing a sales group for marketing the preparation to healthcare providers.
  • the invention relates to a method for conducting a pharmaceutical business by determining an appropriate formulation and dosage of a compound of the invention (e.g., a compound of formula I or II, or a pharmaceutically acceptable salt thereof) to be administered in the treatment of obesity, metabolic syndrome, or a disorder associated with metabolic syndrome (e.g., obesity, diabetes, hypertension, and hyperlipidemia), and licensing, to a third party, the rights for further development and sale of the formulation.
  • a compound of the invention e.g., a compound of formula I or II, or a pharmaceutically acceptable salt thereof
  • a disorder associated with metabolic syndrome e.g., obesity, diabetes, hypertension, and hyperlipidemia
  • PBMC peripheral blood mononuclear cells
  • CM culture medium
  • Frozen human PBMC were drip thawed.
  • the cryopreservation media was slowly diluted in 50 mL fresh culture media, centrifuged for 10 minutes at 1 100 rpm, the media aspirated off of the cell pellet, and the cells resuspended in fresh culture media.
  • the culture medium (CM) for PBMC consisted oiRPMI 1640, 10% FBS, 1% Pen/Strep, 2 mM L-Alanyl-L-glutamine.
  • 96 well plates were seeded at le 4 cells/well in 150 ⁇ 11 CM. Cells were incubated for 1 hour at 37 °C at 5% C0 2 prior to adding test samples, vehicle (DMSO), and dexamethasone (DEX).
  • Table 1 shows the results of these binding assays for several compounds of the invention.
  • Proton and carbon NMR spectra were obtained on a Bruker AC 300 spectrometer at 300 MHz and 75 MHz, respectively. Proton spectra were referenced to tetramethylsilane as an internal standard. Melting points were obtained on a Mel- Temp II apparatus and are uncorrected. HPLC analyses were obtained using a Sunfire CI 8 5 ⁇ Analytical Column and an Alltech Alltima CI 8 Analytical Column Method A (Table 1) with UV detection using standard solvent programs on a Shimadzu Prominence HPLC system.
  • Example 3 Effects of Compounds of the Invention on the Body Weight and Insulin Content of Mice Which Exhibit Diet Induced Obesity
  • mice (4-6 weeks of age) are provided with free access to a high fat diet for 14 weeks. Animals are maintained on a normal phase 12 h light-dark cycle. During this time body weight is recorded weekly. Animals are then singly housed in
  • mice are dosed once daily for six days with vehicle or test compound. During the baseline and treatment period food intake, water intake and body weight are recorded daily. At the completion of dosing, animals are examined and any overt behaviour is recorded. On day six, all the mice are fasted at 16:00. On day seven mice undergo an oral glucose tolerance test (OGTT). Each animal is dosed with vehicle or test compound and 60 minutes later are dosed with D- glucose (2 g/kg po). A baseline blood sample is taken immediately before the glucose load and further blood samples are taken 15, 30 and 60 minutes post glucose administration. All blood samples are taken from the tail vein. Blood samples are taken into lithium heparinised tubes and plasma is separated by centrifugation.
  • OGTT oral glucose tolerance test
  • Plasma samples are frozen at -80 °C and subsequently assayed for glucose and insulin content using commercially available kits and reagents. Area under the curve (AUC) is calculated, and a log transform is used for insulin. Food is re -presented subsequent to the OGTT and final readings are taken on the morning of day eight. Incorporation by Reference

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le traitement du syndrome métabolique et de troubles associés tels que l'obésité, le diabète, l'hypertension et l'hyperlipidémie par administration d'un composé de 2,3-dihydropyrrolizine substitué de manière appropriée représenté par la formule générale (I) ou d'un 1-benzoyl-2-méthylindole substitué de manière appropriée représenté par la formule générale (II) comme décrit : (I) (II)
PCT/US2011/024996 2010-02-17 2011-02-16 Traitement du syndrome métabolique avec de nouvelles amines WO2011103128A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30534010P 2010-02-17 2010-02-17
US61/305,340 2010-02-17

Publications (1)

Publication Number Publication Date
WO2011103128A1 true WO2011103128A1 (fr) 2011-08-25

Family

ID=44483278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/024996 WO2011103128A1 (fr) 2010-02-17 2011-02-16 Traitement du syndrome métabolique avec de nouvelles amines

Country Status (1)

Country Link
WO (1) WO2011103128A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017755A2 (fr) * 2007-07-30 2009-02-05 Ampla Pharmaceuticals Inc. Agonistes de cb1 et agonistes inverses
WO2009073138A2 (fr) * 2007-11-30 2009-06-11 Ampla Pharmaceuticals Inc. Traitement du syndrome métabolique par de nouveaux amides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017755A2 (fr) * 2007-07-30 2009-02-05 Ampla Pharmaceuticals Inc. Agonistes de cb1 et agonistes inverses
WO2009073138A2 (fr) * 2007-11-30 2009-06-11 Ampla Pharmaceuticals Inc. Traitement du syndrome métabolique par de nouveaux amides

Similar Documents

Publication Publication Date Title
US10144709B2 (en) Piperidine compounds, pharmaceutical composition comprising the same and its use
US20080027087A1 (en) CB1 antagonists and inverse agonists
CA2806664A1 (fr) Derives d'arylsulfonamide, compositions en contenant et leurs methodes d'utilisation
AU2018346331B2 (en) Small molecule inhibition of transcription factor SALL4 and uses thereof
CN115304593B (zh) 苯并异噻唑化合物及其药物组合物和应用
WO2024060912A1 (fr) Dérivé de 2h-benzotriazole, son procédé de préparation et composition pharmaceutique le contenant
SU1470190A3 (ru) Способ получени 6-/4 @ -ацетил-2-метилимидазол-1-ил/-8-метил-2-/1Н/-карбостирила
WO2023216533A1 (fr) Alcaloïde indolique, son procédé de préparation et son utilisation
WO2009073138A2 (fr) Traitement du syndrome métabolique par de nouveaux amides
WO2023274258A1 (fr) Composé aromatique à substitution hétéroatomique, son procédé de préparation et son utilisation
KR20100015923A (ko) 수면관련 호흡 장애를 치료하는 방법들 및 수면관련 호흡 장애 치료용 조성물들
NZ195061A (en) 2-amino-3-benzoyl-phenylacetamides;anti-inflammatory and analgesic compositions
WO2011103128A1 (fr) Traitement du syndrome métabolique avec de nouvelles amines
CN101925581A (zh) 新型的咪唑啉基甲基芳基磺酰胺
WO2011103126A1 (fr) Traitement du syndrome métabolique avec des pipéridinamides
JPH05506441A (ja) 加齢関連記憶障害およびその他の認識障害の治療のための化合物
US20090036426A1 (en) CB1 antagonists and inverse agonists
WO2011103127A1 (fr) Traitement du syndrome métabolique avec des pipéridinamides
WO2010120889A1 (fr) Traitement du syndrome métabolique par des amides cycliques
US20090239909A1 (en) Treatment of metabolic syndrome with lactams
WO2010098298A1 (fr) Composition pharmaceutique contenant une combinaison d'un composé possédant une activité inhibitrice de la digestion/absorption des nutriments et d'un dérivé de cyclohexanecarboxamide
CN104447721A (zh) 坎格列净无水化合物
CN104447722A (zh) 坎格列净化合物
WO2023235326A1 (fr) Compositions et méthodes de traitement de porphyries hépatiques avec des inhibiteurs de transport de glycine
WO2023225300A2 (fr) Composés et compositions pharmaceutiques utiles pour la prise en charge de la drépanocytose et d'états pathologiques associés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11745142

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11745142

Country of ref document: EP

Kind code of ref document: A1